Global Plasma-derived Immune Inhibitor Market Size By Type (Blood Products, Non Plasma Derived Coagulation Factor), By Application (Hospital, Medical Center), By Region, And Segment Forecasts, 2023 to...

The Global Plasma-derived Immune Inhibitor Market was valued at USD 5.6 billion in 2023 and is projected to reach USD 9.1 billion by 2031, growing at a CAGR of 6.3% during the forecast period from 2023 to 2031. This growth is driven by the increasing prevalence of autoimmune and rare inflammatory disorders, the rising adoption of plasma-derived therapies, and advancements in biopharmaceutical manufacturing technologies. These immune inhibitors, derived from human plasma, play a crucial role in managing immune responses and are increasingly used for conditions like primary immunodeficiency, hemophilia, and chronic inflammatory demyelinating polyneuropathy (CIDP).

Drivers:

1. Rising Incidence of Autoimmune and Rare Diseases:

Globally, the prevalence of autoimmune and rare immune-related disorders is on the rise, boosting the demand for effective therapies like plasma-derived immune inhibitors. These inhibitors help regulate the overactive immune system, providing relief to patients suffering from chronic and life-threatening conditions.

2. Advancements in Plasma Fractionation Technology:

Innovations in plasma collection, fractionation, and purification processes have significantly improved the efficiency and scalability of producing high-purity immune inhibitors. This has increased product availability and reduced manufacturing bottlenecks.

3. Growing Use in Neurological and Hematological Conditions:

There is a broadening of application areas for plasma-derived immune inhibitors, especially in neurological and hematological settings. Their immunomodulatory effects make them effective in treating diseases like Guillain–Barré syndrome, immune thrombocytopenia, and multiple sclerosis.

Restraints:

1. Limited Plasma Supply and High Dependency on Donors:

The market's growth is constrained by its reliance on voluntary plasma donations, which creates supply-demand imbalances and regional shortages. The long processing time and complex logistics further add to the challenges.

2. High Cost of Therapy:

Plasma-derived therapies are expensive, primarily due to intensive production methods and regulatory compliance costs. This limits their accessibility, especially in low- and middle-income countries.

Opportunity:

1. Expansion into Emerging Markets:

There is significant untapped potential in Asia-Pacific, Latin America, and the Middle East due to growing healthcare infrastructure, rising awareness, and increased government focus on rare disease management.

2. Innovations in Recombinant and Hybrid Therapies:

The integration of recombinant technology with plasma-derived approaches offers a promising area for next-gen immune inhibitors with improved efficacy, safety profiles, and longer half-lives.

Market by System Type Insights:

Based on system type, the Intravenous Immune Globulin (IVIG) segment held the largest share in 2023. IVIG is widely used to treat immune deficiencies and inflammatory disorders due to its rapid action and broad therapeutic applications. However, the Subcutaneous Immune Globulin (SCIG) segment is expected to witness higher growth during the forecast period owing to its self-administration capability, better tolerability, and reduced need for healthcare facility visits.

Market by End-use Insights:

By end use, the Hospitals segment dominated the market in 2023, accounting for over 45% of revenue share. Hospitals remain the primary point of care for administering plasma-derived therapies due to the need for professional oversight and emergency preparedness. However, the Homecare segment is projected to grow rapidly, driven by the adoption of SCIG products and rising patient preference for convenient treatment options.

Market by Regional Insights:

Regionally, North America led the market in 2023, underpinned by robust healthcare infrastructure, a high number of plasma collection centers, and extensive insurance coverage. Europe follows closely, with a well-regulated plasma industry and growing prevalence of rare diseases. Meanwhile, Asia-Pacific is anticipated to be the fastest-growing region, driven by increased healthcare spending, awareness initiatives, and supportive policy frameworks for rare disease treatment.

Competitive Scenario:

Key players in the Global Plasma-derived Immune Inhibitor Market include:

Grifols S.A.

CSL Behring

Octapharma AG

Takeda Pharmaceutical Company Limited

Kedrion Biopharma Inc.

BPL (Bio Products Laboratory)

LFB S.A.

These companies are investing in expanding their plasma collection networks, advancing manufacturing capabilities, and engaging in strategic partnerships to strengthen global supply chains.

Scope of Work – Global Plasma-derived Immune Inhibitor Market

Report Metric Details

Market Size (2023) USD 5.6 billion

Projected Market Size (2031) USD 9.1 billion

Growth Rate (CAGR) 6.3% (2023–2031)

Market Segments By System Type (IVIG, SCIG), By End-use (Hospitals, Clinics, Homecare), By Region

Growth Drivers Increasing prevalence of autoimmune diseases, Technological advancements in plasma fractionation

Opportunities Expansion into emerging markets, Development of recombinant-plasma hybrid therapies

Key Market Developments:

2023: CSL Behring opened a state-of-the-art plasma fractionation facility in the U.S. to increase production efficiency and meet growing global demand.

2024: Grifols partnered with regional blood banks in Asia-Pacific to enhance plasma collection and local manufacturing capabilities.

2025: Octapharma received regulatory approval in Europe for its new SCIG formulation designed for self-administration in pediatric patients.

FAQs:

What is the current market size of the Global Plasma-derived Immune Inhibitor Market?

The market was valued at USD 5.6 billion in 2023.

What is the major growth driver of the Global Plasma-derived Immune Inhibitor Market?

The increasing prevalence of autoimmune and rare inflammatory diseases is a key growth driver.

Which is the largest region during the forecast period in the Global Plasma-derived Immune Inhibitor Market?

North America held the largest share in 2023 and is expected to maintain its lead.

Which segment accounted for the largest market share in Global Plasma-derived Immune Inhibitor Market?

The Intravenous Immune Globulin (IVIG) segment accounted for the largest share in 2023.

Who are the key market players in the Global Plasma-derived Immune Inhibitor Market?